These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Effects of parathyroid hormone (teriparatide) on bone quality in osteoporosis].
    Author: Saito M, Marumo K.
    Journal: Clin Calcium; 2012 Mar; 22(3):343-55. PubMed ID: 22370301.
    Abstract:
    Parathyroid hormone (PTH) acts as an anabolic agent and is used for the treatment for osteoporosis. Daily or once-weekly self-administered subcutaneous injection of human PTH (1-34) (teriparatide) increased bone mineral density (BMD) compared to a placebo in post-menopausal osteoporotic patients. Recently, data have accumulated that collagen cross-link formation in bone affect bone strength. In fact, impaired enzymatic cross-linking and/or an increase in non-enzymatic cross-links, pentosidine, which is a surrogate marker of advanced glycation end products (AGEs) , in bone collagen have been proposed as a major cause of bone fragility in osteoporosis. We reported that teriparatide improves bone collagen cross-link formation, microarchitecture, and bone mass, resulting in the increase of bone strength (Saito M : Osteoporos Int 22 : 2373-83, 2011) . In this review, we described how teriparatide improve bone collagen cross-link formation and mineral qualities.
    [Abstract] [Full Text] [Related] [New Search]